Targeting oncoproteins for degradation by small molecules in myeloid leukemia
摘要：
Acute myeloid leukemia (AML) is a markedly heterogeneous hematological malignancy that is most commonly seen in elderly adults. The response to current therapies to AML is quite variable, and very few new drugs have been recently approved for use in AML. This review aims to discuss the issues with current trial design for AML therapies, including trial end points, patient enrollment, cost of...
展开
DOI：
10.1080/10428194.2017.1403600
年份：
2017
相似文献
参考文献
引证文献
来源期刊
Leukemia & Lymphoma
12/4/2017
辅助模式
0
引用
文献可以批量引用啦~
欢迎点我试用！
